VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion of a €32 million Series B financing round.


VarmX is a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders.

https://www.varmx.com/

Leiden

VarmX

VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

Description

Company Information

Related People

Funding Insights

VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information